RIN Institute Announces First-In-Human Dose of RN-1101, A Monoclonal Antibody For Colorectal Cancer Treatment In Phase I Clinical Trial February 2, 2023
SONIRE Therapeutics Begins a Randomized Phase 2 Clinical Study For Patients With Unresectable Pancreatic Cancer February 3, 2023
Metagen Therapeutics Announces Initial Closing of Series A, Introducing an Unprecedented Potential of Microbiome Therapeutics April 5, 2023
PuREC Partners With Mochida Pharmaceutical To Manufacture Its High-Purity Mesenchymal Stem Cells Towards The Treatment Of Metabolic Bone Diseases May 18, 2023
Koji Yasuda Has Been Appointed as Principal of Fast Track Initiative at Its Boston Office June 7, 2023
Celsius Therapeutics Announces Initiation of Dosing in Phase 1 Clinical Trial of CEL383, an Anti-TREM1 Antibody for the Treatment of Inflammatory Bowel Disease August 3, 2023
Fast Track Initiative Invests in CellFiber, Pioneering Cell Mass Production Technology November 9, 2023
Two of FTI’s portfolios receive significant nondilutive funding from AMED to support their pipeline development December 1, 2023
Global Vascular Secures Series A Funding to Advance Innovative Nanotechnology for Peripheral Artery Disease Treatment December 5, 2023
Fast Track Initiative (FTI) invests in Shinobi Therapeutics, a U.S. and Japan-based company developing hypoimmune iPS cell therapy December 12, 2023
